Virus-like particle–drug conjugate (bel-sar; AU-011) linked to an IRDye 700DX photosensitizer that selectively binds heparan sulfate proteoglycans on tumor cells; activation by near-infrared laser triggers localized photochemical membrane damage causing rapid necrotic and immunogenic cell death.
Virus-like particle–photosensitizer conjugate that binds heparan sulfate proteoglycans on tumor cells; activation by near‑infrared light triggers IRDye 700DX to generate reactive oxygen species and induce localized photochemical membrane damage, leading to rapid necrotic and immunogenic cell death while sparing surrounding healthy tissue.
YES
DIRECT
Bel-sar binds HSPGs on tumor cells; near-infrared light activates the IR700 photosensitizer to generate ROS and cause photochemical membrane damage, leading to rapid necrotic/immunogenic cell death.
Antibody–drug conjugate targeting EGFR and c-MET that delivers a topoisomerase I inhibitor payload to induce DNA damage and tumor cell kill.
Bispecific anti-EGFR/anti-c-MET antibody-drug conjugate that binds EGFR and c-MET on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload which stabilizes TOP1-DNA cleavage complexes, preventing religation and inducing DNA strand breaks, cell-cycle arrest, and apoptosis in EGFR/c-MET–expressing tumors.
YES
DIRECT
Bispecific ADC binds EGFR (and c-MET) on tumor cells, is internalized, and releases a topoisomerase I inhibitor that stabilizes TOP1–DNA cleavable complexes, causing DNA breaks, cell-cycle arrest, and apoptosis.
Antibody–drug conjugate targeting EGFR and c-MET that delivers a topoisomerase I inhibitor payload to induce DNA damage and tumor cell kill.
Bispecific anti-EGFR/anti-c-MET antibody-drug conjugate that binds EGFR and c-MET on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload which stabilizes TOP1-DNA cleavage complexes, preventing religation and inducing DNA strand breaks, cell-cycle arrest, and apoptosis in EGFR/c-MET–expressing tumors.
YES
DIRECT
ADC binds c-MET on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload that induces DNA damage and apoptosis.
Antibody–drug conjugate targeting EGFR and c-MET that delivers a topoisomerase I inhibitor payload to induce DNA damage and tumor cell kill.
Bispecific anti-EGFR/anti-c-MET antibody-drug conjugate that binds EGFR and c-MET on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload which stabilizes TOP1-DNA cleavage complexes, preventing religation and inducing DNA strand breaks, cell-cycle arrest, and apoptosis in EGFR/c-MET–expressing tumors.
NO
INDIRECT
AZD9592 targets EGFR and c-MET on the cell surface, is internalized, and releases a TOP1 inhibitor that induces DNA breaks and apoptosis. TOP1 is the intracellular payload target, not the recognition antigen, so TOP1-expressing cells are not selectively killed unless they also express EGFR/c-MET.
Chimeric monoclonal antibody targeting CD20 on B cells; depletes B cells to suppress humoral immunity and reduce anti-pegloticase antibodies.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells, inducing B-cell depletion via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby suppressing humoral immunity and reducing anti-drug antibody formation.
YES
DIRECT
Binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC by immune effector cells; can also trigger apoptosis.